Skip to main content
. 2017 Sep 19;8:1150. doi: 10.3389/fimmu.2017.01150

Figure 4.

Figure 4

Immunomodulatory B16-derived cells boost T cell cytotoxic activity in vitro. (A) Freshly isolated splenocytes were cultivated with the indicated tumor-derived cells harboring immunomodulators, the graph indicates remaining live tumor cells after incubation with these splenocytes. (B) Flow cytometry of primed splenocytes showed an enrichment of CD8 and CD4 T cells for all immunomodulatory combinations (two-way ANOVA *P < 0.0001). (C) Freshly isolated CD8 T cells were incubated with B16F10 immunomodulatory cells, following Ki67 staining. (D) Freshly isolated CD4 T cells were incubated with B16F10 immunomodulatory cells, following CD25 staining (all comparison of CD4-CD25 and CD8 against F10 made with one way ANOVA and Dunnett’s multiple comparisons had a P value ≤0.005). Graphs of mean and SEM. One way ANOVA and Dunnett’s multiple comparison tests against F10. F10: parental B16F10 cells. RCCs: relative cell counts normalized to the counts in the complete medium (CM). Results from three independent experiments performed in triplicates.